Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctioncoumarin 7-hydroxylase activity

CYP2A6 CYP2A7 CYP2A13

7.71e-083863GO:0008389
GeneOntologyMolecularFunctionarachidonate epoxygenase activity

CYP2A6 CYP2A7 CYP2A13

1.46e-0424863GO:0008392
GeneOntologyMolecularFunctioncyclosporin A binding

PPIG CWC27 NKTR

1.46e-0424863GO:0016018
GeneOntologyMolecularFunctionarachidonate monooxygenase activity

CYP2A6 CYP2A7 CYP2A13

2.09e-0427863GO:0008391
GeneOntologyMolecularFunctionsteroid hydroxylase activity

CYP2A6 CYP2A7 CYP2A13

4.19e-0434863GO:0008395
GeneOntologyMolecularFunctionacetylgalactosaminyltransferase activity

GALNT3 CHSY1 GALNT5

4.57e-0435863GO:0008376
GeneOntologyMolecularFunctionaromatase activity

CYP2A6 CYP2A7 CYP2A13

4.57e-0435863GO:0070330
GeneOntologyMolecularFunctionnucleobase transmembrane transporter activity

SLC43A3 SLC23A1

9.83e-0411862GO:0015205
GeneOntologyMolecularFunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen

CYP2A6 CYP2A7 CYP2A13

1.23e-0349863GO:0016712
GeneOntologyMolecularFunctionpeptidyl-prolyl cis-trans isomerase activity

PPIG CWC27 NKTR

1.31e-0350863GO:0003755
GeneOntologyBiologicalProcessmulti-pass transmembrane protein insertion into ER membrane

NOMO2 NOMO3 NOMO1

5.98e-069873GO:0160063
GeneOntologyBiologicalProcessphenylpropanoid metabolic process

CYP2A6 CYP2A7 CYP2A13

8.51e-0610873GO:0009698
GeneOntologyBiologicalProcesscoumarin metabolic process

CYP2A6 CYP2A7 CYP2A13

8.51e-0610873GO:0009804
GeneOntologyBiologicalProcessleukocyte migration involved in immune response

PLEC HCK

5.26e-053872GO:0002522
GeneOntologyBiologicalProcessprotein insertion into membrane

EGFR NOMO2 NOMO3 NOMO1

5.86e-0550874GO:0051205
GeneOntologyBiologicalProcessepoxygenase P450 pathway

CYP2A6 CYP2A7 CYP2A13

1.05e-0422873GO:0019373
GeneOntologyCellularComponentmulti-pass translocon complex

NOMO2 NOMO3 NOMO1

5.74e-069873GO:0160064
GeneOntologyCellularComponentER membrane insertion complex

NOMO2 NOMO3 NOMO1

2.45e-0514873GO:0072379
MousePhenoabnormal intestinal absorption

CYP2A6 CYP2A7 CYP2A13 EGFR SLC23A1

8.91e-0659675MP:0001666
DomainCyt_P450_E_grp-I_CYP2A-like

CYP2A6 CYP2A7 CYP2A13

3.89e-074873IPR008067
DomainDUF2012

NOMO2 NOMO3 NOMO1

3.89e-074873PF09430
DomainDUF2012

NOMO2 NOMO3 NOMO1

3.89e-074873IPR019008
DomainCarb-bd-like_fold

NOMO2 NOMO3 NOMO1

5.38e-068873IPR013784
DomainCarboxyPept_regulatory_dom

NOMO2 NOMO3 NOMO1

2.70e-0513873IPR014766
Domain-

NOMO2 NOMO3 NOMO1

2.70e-05138732.60.40.1120
DomainCarboxyPept-like_regulatory

NOMO2 NOMO3 NOMO1

6.33e-0517873IPR008969
DomainCyclophilin-type_PPIase_CS

PPIG CWC27 NKTR

8.96e-0519873IPR020892
DomainCyclophilin-type_PPIase

PPIG CWC27 NKTR

1.22e-0421873IPR024936
DomainCyclophilin-like_dom

PPIG CWC27 NKTR

1.41e-0422873IPR029000
DomainCSA_PPIASE_2

PPIG CWC27 NKTR

1.41e-0422873PS50072
DomainPro_isomerase

PPIG CWC27 NKTR

1.41e-0422873PF00160
Domain-

PPIG CWC27 NKTR

1.41e-04228732.40.100.10
DomainCyclophilin-type_PPIase_dom

PPIG CWC27 NKTR

1.41e-0422873IPR002130
DomainCSA_PPIASE_1

PPIG CWC27 NKTR

1.41e-0422873PS00170
DomainCH

CFAP47 LMO7 NAV2 PLEC

3.19e-0470874PF00307
Domain-

CFAP47 LMO7 NAV2 PLEC

3.36e-04718741.10.418.10
DomainCH

CFAP47 LMO7 NAV2 PLEC

3.74e-0473874PS50021
DomainCH-domain

CFAP47 LMO7 NAV2 PLEC

4.15e-0475874IPR001715
DomainCyt_P450_E_grp-I

CYP2A6 CYP2A7 CYP2A13

1.20e-0345873IPR002401
DomainCyt_P450_CS

CYP2A6 CYP2A7 CYP2A13

1.93e-0353873IPR017972
DomainCYTOCHROME_P450

CYP2A6 CYP2A7 CYP2A13

2.38e-0357873PS00086
Domain-

CYP2A6 CYP2A7 CYP2A13

2.50e-03588731.10.630.10
Domainp450

CYP2A6 CYP2A7 CYP2A13

2.50e-0358873PF00067
DomainCyt_P450

CYP2A6 CYP2A7 CYP2A13

2.76e-0360873IPR001128
DomainCH

LMO7 NAV2 PLEC

3.46e-0365873SM00033
PathwayREACTOME_CYP2E1_REACTIONS

CYP2A6 CYP2A7 CYP2A13

1.65e-0511673M27130
PathwayREACTOME_CYP2E1_REACTIONS

CYP2A6 CYP2A7 CYP2A13

2.19e-0512673MM14847
PathwayREACTOME_FATTY_ACIDS

CYP2A6 CYP2A7 CYP2A13

7.96e-0518673MM14841
PathwayREACTOME_XENOBIOTICS

CYP2A6 CYP2A7 CYP2A13

1.70e-0423673M5372
PathwayREACTOME_XENOBIOTICS

CYP2A6 CYP2A7 CYP2A13

2.19e-0425673MM14846
PathwayKEGG_MEDICUS_ENV_FACTOR_NNK_TO_DNA_ADDUCTS

CYP2A6 CYP2A13

2.20e-045672M47808
Pubmed

Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition.

CYP2A6 CYP2A7 CYP2A13

1.51e-08387331645370
Pubmed

A trans-acting locus regulates transcriptional repression of the female-specific steroid 15 alpha-hydroxylase gene in male mice.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838738297477
Pubmed

Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration.

NOMO2 NOMO3 NOMO1

1.51e-08387336011023
Pubmed

Lack of the steroid 15 alpha-hydroxylase gene (Cyp2a-4) in wild mouse strain Mus spretus: rapid evolution of the P450 gene superfamily.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838738188299
Pubmed

Comparison of hamster and mouse reveals interspecies differences in the regulation of hepatic CYP2A isozymes.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838738250953
Pubmed

The structure and characterization of type I P-450(15) alpha gene as major steroid 15 alpha-hydroxylase and its comparison with type II P-450(15) alpha gene.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838732703500
Pubmed

Alteration of the substrate specificity of mouse 2A P450s by the identity of residue-209: steroid-binding site and orientation.

CYP2A6 CYP2A7 CYP2A13

1.51e-08387322217847
Pubmed

Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract.

CYP2A6 CYP2A7 CYP2A13

1.51e-08387322890016
Pubmed

Reciprocal regulation of sex-dependent expression of testosterone 15 alpha-hydroxylase (P-450(15 alpha)) in liver and kidney of male mice by androgen. Evidence for a single gene.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838733346244
Pubmed

Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838732733794
Pubmed

Site-directed mutagenesis of mouse steroid 7 alpha-hydroxylase (cytochrome P-450(7) alpha): role of residue-209 in determining steroid-cytochrome P-450 interaction.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838738484736
Pubmed

Cerium-induced strain-dependent increase in Cyp2a-4/5 (cytochrome P4502a-4/5) expression in the liver and kidneys of inbred mice.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838731417950
Pubmed

Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse.

CYP2A6 CYP2A7 CYP2A13

1.51e-08387324045421
Pubmed

Highly homologous mouse Cyp2a4 and Cyp2a5 genes are differentially expressed in the liver and both express long non-coding antisense RNAs.

CYP2A6 CYP2A7 CYP2A13

1.51e-08387332987105
Pubmed

Mouse steroid 15 alpha-hydroxylase gene family: identification of type II P-450(15)alpha as coumarin 7-hydroxylase.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838732765478
Pubmed

Sexual dimorphism of testosterone 15 alpha-hydroxylase mRNA levels in mouse liver. cDNA cloning and regulation.

CYP2A6 CYP2A7 CYP2A13

1.51e-0838732415518
Pubmed

Silencing of nodal modulator 1 inhibits the differentiation of P19 cells into cardiomyocytes.

NOMO2 NOMO3 NOMO1

1.51e-08387325576386
Pubmed

A human MAP kinase interactome.

DLGAP1 USF3 ANK3 MAP4K5 SH3D19 MCM3AP NAV2 NKTR PLEC CDC42EP3 HCK

3.82e-08486871120936779
Pubmed

Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP.

CYP2A6 CYP2A7 CYP2A13

6.04e-08487310490589
Pubmed

Two steroid 15 alpha-hydroxylase genes and a homologous gene family in mice.

CYP2A6 CYP2A7 CYP2A13

6.04e-0848731970547
Pubmed

Transcriptional regulation by HNF-4 of the steroid 15alpha-hydroxylase P450 (Cyp2a-4) gene in mouse liver.

CYP2A6 CYP2A7 CYP2A13

6.04e-0848739408084
Pubmed

Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology.

NOMO2 NOMO3 NOMO1

6.04e-08487331833031
Pubmed

A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP.

CYP2A6 CYP2A7 CYP2A13

6.04e-0848737565685
Pubmed

A locus for autosomal recessive pseudoxanthoma elasticum, with penetrance of vascular symptoms in carriers, maps to chromosome 16p13.1.

NOMO2 NOMO3 NOMO1

6.04e-0848739267806
Pubmed

The human cytoplasmic dynein interactome reveals novel activators of motility.

PPIG GAPVD1 EDC3 AFTPH MVB12A NOMO2 VPS13C CIAPIN1 EIF4G2 FUS UBE3C PLEC DNMBP

2.04e-07853871328718761
Pubmed

A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

CYP2A6 CYP2A7 CYP2A13

3.01e-0768737668294
Pubmed

Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19.

CYP2A6 CYP2A7 CYP2A13

3.01e-0768738587134
Pubmed

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

CYP2A6 CYP2A7 CYP2A13

5.25e-0778739630227
Pubmed

Organization and evolution of the Cyp2 gene cluster on mouse chromosome 7, and comparison with the syntenic human cluster.

CYP2A6 CYP2A7 CYP2A13

5.25e-07787314630516
Pubmed

Nicalin and its binding partner Nomo are novel Nodal signaling antagonists.

NOMO2 NOMO3 NOMO1

8.39e-07887315257293
Pubmed

Maternal DHA intake in mice increased DHA metabolites in the pup brain and ameliorated MeHg-induced behavioral disorder.

CYP2A6 CYP2A7 CYP2A13

1.26e-06987337838304
Pubmed

Substrate-driven assembly of a translocon for multipass membrane proteins.

NOMO2 NOMO3 NOMO1

1.26e-06987336261522
Pubmed

The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation.

RAE1 EGFR NOMO2 CWC27 MAP4K5 VPS13C AHCTF1 SH3D19 MCM3AP CSRP2 CIAPIN1 EIF4G2 FUS

1.31e-061007871334597346
Pubmed

An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.

NOMO2 DEK NOMO3 NOMO1

1.41e-063387430783098
Pubmed

E-cadherin interactome complexity and robustness resolved by quantitative proteomics.

GAPVD1 ANK3 EGFR LMO7 TMEM51 SH3D19 CIAPIN1 EIF4G2 NAV2 PLEC

1.54e-06565871025468996
Pubmed

An ER translocon for multi-pass membrane protein biogenesis.

NOMO2 NOMO3 NOMO1

2.46e-061187332820719
Pubmed

Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.

CYP2A6 CYP2A7

6.19e-06287212325023
Pubmed

Suppressed hepatocyte proliferation via a ROS-HNE-P21 pathway is associated with nicotine- and cotinine-enhanced alcoholic fatty liver in mice.

CYP2A6 CYP2A13

6.19e-06287230876690
Pubmed

CYP2A5 induction and hepatocellular stress: an adaptive response to perturbations of heme homeostasis.

CYP2A6 CYP2A13

6.19e-06287221395539
Pubmed

Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions.

CYP2A6 CYP2A13

6.19e-06287212162851
Pubmed

Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh.

CYP2A6 CYP2A13

6.19e-0628721302041
Pubmed

Structural alteration of mouse P450coh by mutation of glycine-207 to proline: spin equilibrium, enzyme kinetics, and heat sensitivity.

CYP2A6 CYP2A13

6.19e-0628728395817
Pubmed

Absence of cytochrome P450 2A5 enhances alcohol-induced liver injury in mice.

CYP2A6 CYP2A13

6.19e-06287225804444
Pubmed

Effect of pyrazole, cobalt and phenobarbital on mouse liver cytochrome P-450 2a-4/5 (Cyp2a-4/5) expression.

CYP2A6 CYP2A13

6.19e-0628721520280
Pubmed

Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.

CYP2A6 CYP2A13

6.19e-06287223917075
Pubmed

CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.

CYP2A6 CYP2A7

6.19e-06287216636685
Pubmed

Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.

CYP2A6 CYP2A13

6.19e-06287227902773
Pubmed

Circadian Regulation of Hepatic Cytochrome P450 2a5 by Peroxisome Proliferator-Activated Receptor γ.

CYP2A6 CYP2A13

6.19e-06287230154104
Pubmed

Expression of CYP2A genes in human liver and extrahepatic tissues.

CYP2A7 CYP2A13

6.19e-06287210353262
Pubmed

Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.

CYP2A6 CYP2A13

6.19e-06287221418183
Pubmed

Fused in sarcoma (FUS) interacts with the cytolinker protein plectin: implications for FUS subcellular localization and function.

FUS PLEC

6.19e-06287222240165
Pubmed

Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.

CYP2A6 CYP2A13

6.19e-06287219923441
Pubmed

Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression.

CYP2A6 CYP2A13

6.19e-06287212499123
Pubmed

Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver.

CYP2A6 CYP2A13

6.19e-06287222497566
Pubmed

The role of CYP2A5 in liver injury and fibrosis: chemical-specific difference.

CYP2A6 CYP2A13

6.19e-06287226363552
Pubmed

Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes.

CYP2A6 CYP2A13

6.19e-0628722712571
Pubmed

Genetic Variants in EGFR/PLCE1 Pathway Are Associated with Prognosis of Esophageal Squamous Cell Carcinoma after Radical Resection.

EGFR PLCE1

6.19e-06287231209807
Pubmed

EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling.

EGFR FUS

6.19e-06287232678881
Pubmed

Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.

CYP2A6 CYP2A13

6.19e-06287222696418
Pubmed

Nicotine enhances alcoholic fatty liver in mice: Role of CYP2A5.

CYP2A6 CYP2A13

6.19e-06287230222954
Pubmed

Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver.

CYP2A6 CYP2A13

6.19e-0628727543189
Pubmed

Characterization and regulation of sex-specific mouse steroid hydroxylase genes.

CYP2A6 CYP2A13

6.19e-0628722372744
Pubmed

The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

CYP2A6 CYP2A7

6.19e-0628722322567
Pubmed

Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.

CYP2A6 CYP2A13

6.19e-06287221473878
Pubmed

The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis.

CYP2A6 CYP2A13

6.19e-0628727581481
Pubmed

Expression and alternative splicing of the cytochrome P-450 CYP2A7.

CYP2A6 CYP2A7

6.19e-0628727864805
Pubmed

Interstrain differences in the expression and activity of Cyp2a5 in the mouse liver.

CYP2A6 CYP2A13

6.19e-06287228298240
Pubmed

Genetic polymorphisms for a phenobarbital-inducible cytochrome P-450 map to the Coh locus in mice.

CYP2A6 CYP2A13

6.19e-0628726309775
Pubmed

Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.

CYP2A6 CYP2A13

6.19e-06287222262919
Pubmed

Modulation of cytochrome P450 2A5 activity by lipopolysaccharide: low-dose effects and non-monotonic dose-response relationship.

CYP2A6 CYP2A13

6.19e-06287225635819
Pubmed

Genetic variation between mice in their metabolism of coumarin and its derivatives.

CYP2A6 CYP2A13

6.19e-062872566237
Pubmed

Identification and characterization of a 44 kDa protein that binds specifically to the 3'-untranslated region of CYP2a5 mRNA: inducibility, subcellular distribution and possible role in mRNA stabilization.

CYP2A6 CYP2A13

6.19e-0628728611142
Pubmed

Coumarin toxicity in different strains of mice.

CYP2A6 CYP2A13

6.19e-062872665441
Pubmed

Essential role of the cytochrome P450 enzyme CYP2A5 in olfactory mucosal toxicity of naphthalene.

CYP2A6 CYP2A13

6.19e-06287224104196
Pubmed

Establishment and analysis of a mouse model that regulates sex-related differences in liver drug metabolism.

CYP2A6 CYP2A7 CYP2A13

6.73e-061587329968852
Pubmed

Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases.

PPIG CWC27 NKTR

6.73e-061587320676357
Pubmed

Zinc Fingers and Homeoboxes 2 (Zhx2) Regulates Sexually Dimorphic Cyp Gene Expression in the Adult Mouse Liver.

CYP2A6 CYP2A7 CYP2A13

1.00e-051787327197076
Pubmed

Mitochondrial phosphoproteome revealed by an improved IMAC method and MS/MS/MS.

CYP2A6 CYP2A7 CYP2A13 PLEC

1.30e-055787417208939
Pubmed

Molecular genetics of the human cytochrome P450 monooxygenase superfamily.

CYP2A6 CYP2A7 CYP2A13

1.67e-05208739890157
Pubmed

Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.

GAPVD1 EGFR NOMO2 MAP4K5 NUP133 NKTR PLEC DEK HCK NOMO3 NOMO1

1.70e-05910871136736316
Pubmed

Expression of cytochrome P450 2A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress.

CYP2A6 CYP2A13

1.85e-05387218068688
Pubmed

CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism.

CYP2A6 CYP2A7

1.85e-05387211960914
Pubmed

Rip locus: regulation of female-specific isozyme (I-P-450(16 alpha) of testosterone 16 alpha-hydroxylase in mouse liver, chromosome localization, and cloning of P-450 cDNA.

CYP2A6 CYP2A13

1.85e-0538723219345
Pubmed

Zfp30, a KRAB domain containing zinc finger protein gene, maps to mouse chromosome 7.

CYP2A6 CYP2A13

1.85e-0538727849402
Pubmed

Mechanisms of olfactory toxicity of the herbicide 2,6-dichlorobenzonitrile: essential roles of CYP2A5 and target-tissue metabolic activation.

CYP2A6 CYP2A13

1.85e-05387220840855
Pubmed

Epidermal growth factor receptor-PI3K signaling controls cofilin activity to facilitate herpes simplex virus 1 entry into neuronal cells.

EGFR PIK3CG

1.85e-05387224425731
Pubmed

Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.

EGFR PIK3CG

1.85e-05387219787273
Pubmed

Close linkage of the cytochrome P450IIA gene subfamily (Cyp2a) to Cyp2b and Coh on mouse chromosome 7.

CYP2A6 CYP2A13

1.85e-0538721973143
Pubmed

A novel defensive mechanism against acetaminophen toxicity in the mouse lateral nasal gland: role of CYP2A5-mediated regulation of testosterone homeostasis and salivary androgen-binding protein expression.

CYP2A6 CYP2A13

1.85e-05387221252290
Pubmed

Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate Cytochrome P450 2a5 transcription through a common E-box site.

CYP2A6 CYP2A13

1.85e-05387217466327
Pubmed

Generation and characterization of a novel Cyp2a(4/5)bgs-null mouse model.

CYP2A6 CYP2A13

1.85e-05387223073733
Pubmed

Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes.

CYP2A6 CYP2A13

1.85e-05387218602936
Pubmed

Ethanol induction of CYP2A5: role of CYP2E1-ROS-Nrf2 pathway.

CYP2A6 CYP2A13

1.85e-05387222552773
Pubmed

Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital.

CYP2A6 CYP2A13

1.85e-05387211106424
Pubmed

Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2.

CYP2A6 CYP2A13

1.85e-05387217303623
Pubmed

Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.

EGFR PIK3CG

1.85e-05387219229860
Pubmed

Novel interactions of ankyrins-G at the costameres: the muscle-specific Obscurin/Titin-Binding-related Domain (OTBD) binds plectin and filamin C.

ANK3 PLEC

1.85e-05387221223964
Pubmed

Mitochondrial targeting of bilirubin regulatory enzymes: An adaptive response to oxidative stress.

CYP2A6 CYP2A13

1.85e-05387225478736
Pubmed

CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126.

CYP2A6 CYP2A7

1.85e-05387225710939
Pubmed

High-fat diet induces fibrosis in mice lacking CYP2A5 and PPARα: a new model for steatohepatitis-associated fibrosis.

CYP2A6 CYP2A13

1.85e-05387232877213
InteractionCYP2A7 interactions

CYP2A6 CYP2A7 CYP2A13

7.77e-083873int:CYP2A7
Cytoband19q13.2

CYP2A6 CYP2A7 CYP2A13 ZNF224 LGALS4

1.60e-0516487519q13.2
GeneFamilyCyclophilin peptidylprolyl isomerases

PPIG CWC27 NKTR

2.63e-0519563909
GeneFamilyNucleoporins

RAE1 AHCTF1 NUP133

1.31e-04325631051
GeneFamilyCytochrome P450 family 2

CYP2A6 CYP2A7 CYP2A13

1.72e-04355631001
GeneFamilyEndogenous ligands|Minor histocompatibility antigens

NUP133 HEATR1 KDM5D

5.28e-0451563870
GeneFamilyPolypeptide N-acetylgalactosaminyltransferases

GALNT3 GALNT5

1.73e-0320562433
CoexpressionNAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE

USF3 GALNT3 ANK3 NOMO2 AHCTF1 NKTR HEATR1 FUS GFM1 NOMO3 NOMO1

4.90e-074748711M40991
CoexpressionNAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE

PPIG ANK3 LMO7 AHCTF1 SNRK NKTR HEATR1 FUS ESCO1

3.37e-06363879M41103
CoexpressionTHAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_UP

DNAJC10 VPS13C EIF4G2 CHSY1 SLC43A3 GFM1

4.21e-06127876M40905
CoexpressionHAMAI_APOPTOSIS_VIA_TRAIL_UP

BPTF PPIG CWC27 VPS13C AHCTF1 ZNF397 NKTR VPS26A RPGR DEK KIF20B

1.11e-056568711M18979
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_DN

BPTF GAPVD1 EGFR MAP4K5 AHCTF1 NUP133 CHSY1 RPGR DNMBP DEK KIF20B PLCE1

2.55e-058568712M4500
CoexpressionGSE22140_HEALTHY_VS_ARTHRITIC_MOUSE_CD4_TCELL_DN

PIK3CG LTA4H RPGR PLEC GSTO1 CDC42EP3

5.38e-05199876M7651
CoexpressionGSE12845_IGD_NEG_BLOOD_VS_DARKZONE_GC_TONSIL_BCELL_DN

BPTF DNAJC10 HIKESHI MAP4K5 ZKSCAN7 NKTR

5.38e-05199876M3197
CoexpressionAIZARANI_LIVER_C20_LSECS_3

TMEM51 AHCTF1 CHSY1 SNRK ADGRF5 RPGR DNMBP

5.77e-05295877M39121
ToppCellCD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster

GAPVD1 NOMO2 VPS13C AHCTF1 NKTR HEATR1 ZNF224 FUS

3.99e-091918789454f642c3621370fa23640b631301346b300950
ToppCellControl-Epithelial-Club|World / Disease state, Lineage and Cell class

CYP2A6 CYP2A7 ANK3 EGFR LMO7 NAV2 ADGRF5

8.15e-081868779798428691408e17ff2af2fe2d1b345f074d67e4
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5 LNX1

8.76e-081888774bdf8d49af0e9da349b16e3f012e1b0eec04cc4f
ToppCellControl-Epithelial-Club|Control / Disease state, Lineage and Cell class

CYP2A6 CYP2A7 ANK3 EGFR LMO7 NAV2 ADGRF5

1.01e-07192877d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16
ToppCellLPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

PLB1 LMO7 VPS13C PKHD1 NAV2 LTA4H GALNT5

1.21e-07197877b94645d57efe8d9e032bffb8c89af1f425c6421e
ToppCellLPS_IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

GALNT3 ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.25e-07198877285f729140b1df029c24f6ca1d2438470ac51794
ToppCellControl|World / group, cell type (main and fine annotations)

DLGAP1 ANK3 EGFR LMO7 NAV2 ADGRF5

9.74e-07168876a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCellLPS_only-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 LTA4H GALNT5 LNX1

1.41e-06179876fd2cbee532e7b44113410dca82aec7db1a7fb69f
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DLGAP1 EGFR LMO7 PKHD1 NAV2 GALNT5

1.41e-0617987604ce3673e46606f63d9c87bcba3a64c96817d812
ToppCellLPS_only-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 LTA4H GALNT5 LNX1

1.50e-061818760513b9e6673ff7bf8e72ba123ca3794b65d10170
ToppCellControl-Epithelial_cells-Airway_club|Control / group, cell type (main and fine annotations)

CYP2A6 CYP2A7 ANK3 LMO7 NAV2 ADGRF5

1.50e-06181876c755d23dd9aabc717dc73e2b3fa99a1f751e6507
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.55e-0618287617ed11a7ea366dd3106400511d5e628d3f1a9c3e
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.65e-06184876ab2f06906fc7a9931dfa0864ef506832b07fb93e
ToppCellCV-Moderate-7|Moderate / Virus stimulation, Condition and Cluster

GAPVD1 NOMO2 VPS13C AHCTF1 HEATR1 FUS

1.71e-06185876a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.71e-06185876fefaf227d89f680d6f3e91c4a94e26ab4d0dc6c3
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DLGAP1 EGFR LMO7 PKHD1 NAV2 GALNT5

1.76e-061868764e94158db52df41d71e67b02b9895a358eebee0f
ToppCellCV-Moderate-7|CV / Virus stimulation, Condition and Cluster

GAPVD1 NOMO2 VPS13C AHCTF1 HEATR1 FUS

1.76e-061868768571956890fc9894d766ba294a28e376b4aba428
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.76e-06186876e83718fabb057100835d3357df407f283d23fe16
ToppCellLPS-antiTNF-Epithelial_alveolar|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.82e-06187876201ff693e4756ee3e44762885b3a303a77eb535b
ToppCellLPS-IL1RA-Epithelial_alveolar|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.87e-061888766164d467b612767ceba15de34176bcc8e8c36ab8
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 NAV2 LTA4H GALNT5

1.87e-0618887643a0508d2524a5b310e89e9422843dcaab999bc3
ToppCellIPF-Epithelial-Club|World / Disease state, Lineage and Cell class

CYP2A6 CYP2A7 ANK3 LMO7 NAV2 ADGRF5

2.05e-061918763c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954
ToppCellCOPD-Endothelial-VE_Arterial|Endothelial / Disease state, Lineage and Cell class

EGFR NOMO2 CHSY1 CDC42EP3 NOMO3 NOMO1

2.05e-06191876ef16ad1c1cd2c0c0377957398c98775b62a81754
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ANK3 LMO7 PKHD1 NAV2 ADGRF5 DESI2

2.05e-06191876ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCellEpithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|World / Lineage, Cell type, age group and donor

ANK3 EGFR LMO7 PKHD1 NAV2 ADGRF5

2.05e-06191876d3733c8c4bda70c4390e5601fdda6188a64be944
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ANK3 LMO7 PKHD1 NAV2 ADGRF5 DESI2

2.12e-0619287629f49f00770c991b5f27e4cb701dd2d2d6cb7178
ToppCellEpithelial-club_cell|World / Lineage, Cell type, age group and donor

CYP2A6 CYP2A7 ANK3 LMO7 NAV2 CNTN3

2.18e-061938762bdd09004fa433550958ec42ba4b06271a4aaf7c
ToppCellChildren_(3_yrs)-Epithelial-club_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

CYP2A6 CYP2A7 ANK3 LMO7 CNTN3 PLCE1

2.31e-06195876dccc32fcf772e2504de7f663ef0a5bd8e23e92fc
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

GALNT3 ANK3 LMO7 NAV2 LTA4H GALNT5

2.46e-061978761485933986921ff45669d9b7501c8d17050b3e97
ToppCell(11)_FOXN4+-(2)_GFP_FOXI1|(11)_FOXN4+ / shred by cell type by condition

BPTF PPIG EGFR MAP4K5 VPS13C KIF20B

2.53e-0619887676d40b8c2f8399725b3a62ee2ae0896559cf91eb
ToppCell(03)_KRT6B+-(2)_GFP_FOXI1|(03)_KRT6B+ / shred by cell type by condition

BPTF PPIG LMO7 MAP4K5 VPS13C DEK

2.60e-06199876c425e7975f492ed5cfcca022248adb627e1d27d4
ToppCellLPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ANK3 LMO7 NAV2 LTA4H GALNT5 ADAT1

2.60e-06199876121de4e02585de3a3010398387c523bacf8ce546
ToppCellLPS_IL1RA_TNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

GALNT3 ANK3 LMO7 NAV2 LTA4H GALNT5

2.68e-06200876e8db082aa4d0597500e4f16a5c0ea3e62c6c59ae
ToppCell5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

WNT16 CNTN3 ADPRHL1 AGBL2 SLC23A1

1.30e-05154875ec56b7fb88e39041416c384f371c767f3b4e92fa
ToppCellPND10-Epithelial-Epithelial_Airway-Neurosecretory-Secretory-Secretory_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PLB1 GALNT3 GALNT5 LNX1 GSTO1

1.76e-051648756ea188e17895961cd112152fb111d08641cc5e45
ToppCellControl-Epithelial_cells-ECM-high_epithelial|Control / group, cell type (main and fine annotations)

ANK3 EGFR LMO7 NAV2 ADGRF5

2.09e-05170875e2023d66e70983c87dacbd6181d3426488d1fc57
ToppCellControl-Epithelial_alveolar-AT_1-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DLGAP1 LMO7 PKHD1 NAV2 GALNT5

2.53e-051778759af14a056eb6d88c6f11b09f6d4c0d3448d647d5
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|Children_(3_yrs) / Lineage, Cell type, age group and donor

ANK3 EGFR LMO7 NAV2 GALNT5

2.67e-05179875cb38b54261a7af5ee3347e64c8aa880a77ed0763
ToppCelldroplet-Heart-nan-3m-Neuronal-cardiac_neuron|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DLGAP1 ANK3 ZFHX4 ZNF184 PLCE1

2.75e-05180875da723df348d7b8449bb1124f23fe6fa706412adb
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 LMO7 NAV2 LTA4H GALNT5

2.75e-05180875b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCelldroplet-Heart-nan-3m-Neuronal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DLGAP1 ANK3 ZFHX4 ZNF184 PLCE1

2.75e-051808755b146a94708b3c3610542a4d0925f3f7a2b19185
ToppCelldroplet-Heart-nan-3m-Neuronal-cardiac_neuron|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DLGAP1 ANK3 ZFHX4 ZNF184 PLCE1

2.75e-0518087550758b1e7be2e43f83c10ab106900c067e61f5f7
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 PKHD1 NAV2 GALNT5

2.82e-05181875b45b11428d13950369347e051d4d517efb2bd4fd
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ANK3 LMO7 NAV2 LTA4H ADGRF5

2.82e-05181875576da14ab3107f89e1f44a4a439d1bef5bb42370
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 PKHD1 NAV2 GALNT5

2.97e-05183875ff6dde877659cde9daa3263db0932c9c9ef1adac
ToppCellLPS_only-Epithelial_alveolar-AT_2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 LMO7 LTA4H GALNT5 LNX1

2.97e-05183875e972432dd4d1bd31bb0982f4df3061e5e152658f
ToppCellCOVID-19-Epithelial_cells-AT2|COVID-19 / group, cell type (main and fine annotations)

DLGAP1 ANK3 EGFR LMO7 ADGRF5

3.05e-05184875369b82f793deab672204558ae4e112cfa5aa9ccc
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 NAV2 LTA4H GALNT5

3.05e-051848757cc5796557379c3d1db078c1aeda40659c6e401c
ToppCell368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)

USF3 AFTPH GALNT3 SH3D19 PLEC

3.05e-05184875e6bf826be31e1723e24c366fc5a1cee9b15589bc
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 PKHD1 LTA4H GALNT5

3.05e-05184875cdf6f1c6cce97a7effa0c55959652e2c0b6992b3
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 LMO7 NAV2 LTA4H GALNT5

3.05e-05184875d0c212a8fbaad24597a84018442b25c61c17ea58
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-AT2_Progenitor|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 LMO7 NAV2 LTA4H GALNT5

3.13e-05185875929b68b05b7686341329ac756d7df172cb4b810b
ToppCellLPS_only-Epithelial_alveolar|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ANK3 EGFR LMO7 LTA4H GALNT5

3.21e-05186875e0a2ea4b46af742bc7c9b2072bb85e27d5c92712
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 PKHD1 NAV2 GALNT5

3.21e-051868753aebe163799109ffc67e4e10ee47c2dd0886a92c
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

DLGAP1 ANK3 NAV2 LTA4H ADGRF5

3.21e-05186875acfa68a2afb7d2b51c9b469a1965fe5cc5d5e64e
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ANK3 LMO7 PKHD1 ADGRF5 DESI2

3.30e-051878755df9e1f5ca32217af255e76e6fb5afa346337811
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

EGFR LMO7 PKHD1 NAV2 GALNT5

3.30e-0518787558d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCellP28-Epithelial-alveolar_epithelial_cell-type_I_pneumocyte|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

PLB1 LMO7 NAV2 GSTO1 HCK

3.30e-05187875a4b41904ba05eb76212c949fc3ac197f906c8351
ToppCellCOVID-19-Epithelial_cells|COVID-19 / group, cell type (main and fine annotations)

ANK3 EGFR LMO7 NAV2 ADGRF5

3.38e-05188875c9cdee6f8d42ee69f5fb335f25084603c511bd29
ToppCellIPF-Epithelial-Club|IPF / Disease state, Lineage and Cell class

CYP2A6 ANK3 LMO7 NAV2 ADGRF5

3.47e-05189875f3fcef008ef252b29ac6d567fef27f9acf9cd70f
ToppCellfacs-Limb_Muscle-ForelimbandHindlimb-3m-Endothelial-endothelial_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-0519087538a815abf0ac5cac6071737cadc54a514f62d37d
ToppCelldroplet-Fat-BAT+GAT+MAT-30m-Endothelial-endothelial_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-05190875c8370c922e0cf0e0c36e02e1ed2b4053ad6a8073
ToppCellPND10|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

BPTF GAPVD1 EIF4G2 SNRK ADGRF5

3.56e-05190875d67e2814047c8df2ae4b7bc8be9539f5df6ecef2
ToppCelldroplet-Fat-BAT+GAT+MAT-30m-Endothelial-nan|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-051908755174f91a880f85bb20806023aa68bd4b8ca24ea5
ToppCellfacs-Limb_Muscle-ForelimbandHindlimb-3m-Endothelial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-05190875bb1476b44dd49e1dd52a636a91c4600b6d4fbe2e
ToppCelldroplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Endothelial-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-05190875f98e2d45fab7d9e16629d7f13cc2ccfb939ef4dd
ToppCellfacs-Limb_Muscle-ForelimbandHindlimb-3m-Endothelial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-05190875d180205c70b5ca9bc5a01a2e6cb42fcebc7f630d
ToppCelldroplet-Fat-BAT+GAT+MAT-30m-Endothelial|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.56e-0519087590e494cbfbed33a3a0d29bb7dae83f0c81580bcf
ToppCellChildren_(3_yrs)-Epithelial-club_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor

CYP2A6 CYP2A7 ANK3 LMO7 CNTN3

3.65e-0519187523776c7302cead3881b39127398f3b3e0d27885e
ToppCelldroplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ZFHX4 EGFR VPS13C NKTR SLC43A3

3.65e-051918757d1595e616f6f111fc2f5bc1b179c5d67d624cc9
ToppCelldroplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Endothelial-endothelial_cell_of_coronary_artery|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.65e-051918755020fe6c3452e7fab57847f5043d28ebbc5aa381
ToppCelldroplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.74e-0519287524d28e28a5c54ca7770f7e5ad7f4d00039e0aaf9
ToppCellEpithelial|World / Lineage, Cell type, age group and donor

ANK3 EGFR LMO7 NAV2 ADGRF5

3.74e-05192875499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCellfacs-Diaphragm-Limb_Muscle-3m-Endothelial-nan|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.74e-051928758f20d3511dcb44445592b17d005a53da0052ae56
ToppCellfacs-Diaphragm-Limb_Muscle-3m-Endothelial-endothelial_cell|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.74e-051928750986b7900021efe2a4df84a935e7c9a0af1b0e57
ToppCellAdult-Epithelial|Adult / Lineage, Cell type, age group and donor

ANK3 EGFR LMO7 NAV2 ADGRF5

3.74e-05192875efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCellfacs-Diaphragm-Limb_Muscle-3m-Endothelial|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

3.74e-05192875b28d294e42b303d1db6060231d84d7b9e4d9fccf
ToppCellFetal_29-31_weeks-Epithelial|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ANK3 LMO7 PKHD1 NAV2 ADGRF5

3.83e-05193875a0ca3231992f14abcf1a6129573bace320e89d2a
ToppCell3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CYP2A6 CYP2A7 LMO7 NAV2 ADGRF5

3.93e-051948755b29c843186c2394f5bec3b1d5ae284a0d931d85
ToppCellnucseq-Epithelial-Epithelial_Alveolar|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ANK3 EGFR LMO7 NAV2 ADGRF5

3.93e-0519487553f3e49e91b1096f3226010e2de767efb490dfe4
ToppCell3'-Parenchyma_lung-Epithelial-Epithelial_transtional|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CYP2A6 CYP2A7 LMO7 NAV2 ADGRF5

3.93e-05194875ebcf6c6d0eb20a5d422becf5a730089230c8ba9a
ToppCell3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CYP2A6 CYP2A7 LMO7 NAV2 ADGRF5

3.93e-051948758c6e5ba27a988e0cd6b8c25cb9a30a0da2b1f7f9
ToppCell3'-Parenchyma_lung-Epithelial-Epithelial_transtional-epithelial_cell_of_lung-Transitional_Club-AT2-Transitional_Club-AT2_L.0.4.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CYP2A6 CYP2A7 LMO7 NAV2 ADGRF5

3.93e-051948756e78e3046c5b172af92a84e25f982377a0aaac58
ToppCellIPF-Multiplet-Multiplet|IPF / Disease state, Lineage and Cell class

CFAP47 ANK3 LMO7 NAV2 ADGRF5

4.02e-05195875fce0c29574bb7aab181b9c00feb42681e285d1f2
ToppCellControl-Multiplet|Control / Disease state, Lineage and Cell class

ANK3 EGFR LMO7 NAV2 ADGRF5

4.02e-05195875618900c80bea09d46dad3f741bd1bff8bf0a64ee
ToppCelldroplet-Limb_Muscle-MUSCLE-1m-Endothelial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

4.02e-0519587598d79f6a8a5cc86a219efe8db9f9535d7ad4c5be
ToppCelldroplet-Limb_Muscle-MUSCLE-1m-Endothelial-endothelial_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

4.02e-05195875ea0627ffe1750dbdd48006d251c0ba4cadd32faf
ToppCelldroplet-Limb_Muscle-MUSCLE-1m-Endothelial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LMO7 SNRK ADGRF5 LNX1 CDC42EP3

4.02e-051958753b95a989adb99591b44704ff4c496a1c6cb0bb18
ToppCellIPF-Multiplet|IPF / Disease state, Lineage and Cell class

CFAP47 ANK3 LMO7 NAV2 ADGRF5

4.02e-05195875eacc0449ae6f3ad8002268cd061467684c6fb9a7
ToppCellControl-Multiplet-Multiplet|Control / Disease state, Lineage and Cell class

ANK3 EGFR LMO7 NAV2 ADGRF5

4.02e-0519587506ac685855e14e4dd2cbe6d0e73f894f2eeff91f
ToppCellnucseq-Epithelial|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

ANK3 EGFR LMO7 NAV2 ADGRF5

4.02e-051958759406866f99555198a9be311fbd65751b70f35446
ToppCell(1)_T_cells-(1)_T_CD4_naive|(1)_T_cells / Spleen cell shreds - cell class (v1) and cell subclass (v1)

BPTF ANK3 LMO7 ZNF397 NKTR

4.02e-05195875d3fa551bc6f5ee5890af1040415e61ecd5d46201
ToppCellControl-Epithelial|Control / Disease state, Lineage and Cell class

ANK3 EGFR LMO7 NAV2 ADGRF5

4.02e-051958751798c3b89b1b5ff4f5777d2b9f52dc81cdad28fa
ToppCellCOPD-Multiplet-Multiplet|COPD / Disease state, Lineage and Cell class

CFAP47 ANK3 LMO7 NAV2 ADGRF5

4.12e-05196875af4cdc61830685a888a1209826c23bcf54a43084
ToppCellCOPD-Multiplet|COPD / Disease state, Lineage and Cell class

CFAP47 ANK3 LMO7 NAV2 ADGRF5

4.12e-051968756d02d494196e3f857d53eea46d9419690d43beca
ToppCellControl_saline-Epithelial_alveolar-AT_2-Differentiating_AT2|Control_saline / Treatment groups by lineage, cell group, cell type

GALNT3 ANK3 LMO7 NAV2 GALNT5

4.22e-0519787544a59dfb889577b3160a5b13ada1276771a00241
ToppCellrenal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

DLGAP1 ANK3 LMO7 TMEM51 PKHD1

4.22e-051978757e93a97b5ac5ae2f77a4b3141082a1463fed00dd
ToppCellsaliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

GALNT3 EGFR MAP4K5 NAV2 GALNT5

4.22e-05197875d6c9da7a3a6d2bcb13e2fc6605c8a59e7fb121c5
ToppCellsaliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

GALNT3 EGFR MAP4K5 NAV2 GALNT5

4.22e-0519787580b05c8ad9c1edc5dea3236079372475431343fe
ToppCellLPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

ANK3 EGFR LMO7 PKHD1 GALNT5

4.22e-051978753d13a4f2e86422900ee2194e8a1fd1cf9750d5d3
Drug2'-methoxyacetophenone

CYP2A6 CYP2A7 CYP2A13

5.39e-083873CID000068481
Drugnaphthalene

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H FUS PLEC

4.62e-07123877CID000000931
Drug1,1-dichloroethylene epoxide

CYP2A6 CYP2A7 PPIG CYP2A13 GSTO1

1.34e-0650875CID000119521
Drugdichloroacetaldehyde

CYP2A6 CYP2A7 PPIG CYP2A13 GSTO1

1.98e-0654875CID000006576
DrugN-nitrosoguvacoline

CYP2A6 PPIG CYP2A13

4.45e-069873CID000062103
Drug3-(methylnitrosamino)propionaldehyde

CYP2A6 PPIG CYP2A13

4.45e-069873CID000098533
Drugmetyrapone

DMGDH CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H PLEC

5.68e-06179877CID000004174
DrugCaptopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A

BPTF PPIG ANK3 EGFR NKTR DESI2 FUS

5.68e-061798774585_DN
Drug5,6-epoxyeicosatrienoic acid

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H

6.26e-0668875CID000001778
Drugbenzphetamine

DMGDH CYP2A6 CYP2A7 PPIG CYP2A13 PLEC

6.42e-06119876CID000002341
Drug8(9)-EET

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H

6.72e-0669875CID000001901
DrugAC1O5XSP

CYP2A6 CYP2A7 CYP2A13 LTA4H

8.45e-0634874CID006442739
DrugD-702

CYP2A6 PPIG CYP2A13

8.70e-0611873CID000054077
DrugBP-7,8-diol

CYP2A6 CYP2A7 PPIG CYP2A13 GSTO1

1.23e-0578875CID000025892
DrugDocetaxel trihydrate

CYP2A6 CYP2A7 PPIG CYP2A13 CALCA EGFR PLEC

1.25e-05202877CID000003143
Drugpropargyl ether

CYP2A6 CYP2A13

1.44e-052872ctd:C531209
DrugHempa

CYP2A6 CYP2A13

1.44e-052872ctd:D006492
Drugnicotine imine

CYP2A6 CYP2A13

1.44e-052872ctd:C034629
Drugalpha-nicotyrine

CYP2A6 CYP2A13

1.44e-052872ctd:C008615
DrugN-nitrosoguvacoline

CYP2A6 CYP2A13

1.44e-052872ctd:C036676
Drug11,14,15-THET

CYP2A6 CYP2A7 CYP2A13 LTA4H

1.48e-0539874CID006439531
DrugMnPN

CYP2A6 PPIG CYP2A13

1.90e-0514873CID000062163
DrugN-nitrosomethylaniline

CYP2A6 CYP2A7 CYP2A13

1.90e-0514873CID000011957
Drug11,12,15-trihydroxyeicosatrienoic acid

CYP2A6 CYP2A7 CYP2A13 LTA4H

1.99e-0542874CID006439610
Drug14(15)-EpETrE

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H

2.34e-0589875CID000001431
Drugisopimpinellin

CYP2A6 KDM5D LGALS4

2.37e-0515873CID000068079
Drug4-aminobiphenyl

CYP2A6 PPIG CYP2A13 GSTO1 MOCS1

2.75e-0592875CID000007102
DrugAC1L1BEQ

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H

2.89e-0593875CID000001407
DrugC14802

CYP2A6 CYP2A7 CYP2A13 GSTO1

3.13e-0547874CID011954053
Drugnitro-L

CYP2A6 CYP2A7 PPIG CYP2A13

3.40e-0548874CID000006849
DrugC14800

CYP2A6 CYP2A7 CYP2A13 GSTO1

3.40e-0548874CID011954051
Drug19-HETE

CYP2A6 CYP2A7 PPIG CYP2A13

3.70e-0549874CID006439528
Drugbromobenzene-3,4-oxide

CYP2A6 CYP2A7 CYP2A13 GSTO1

3.70e-0549874CID000108121
DrugPCB 77

CYP2A6 CYP2A7 PPIG CYP2A13 GSTO1

3.73e-0598875CID000036187
Drugbromobenzene-2,3-oxide

CYP2A6 CYP2A7 CYP2A13 GSTO1

4.00e-0550874CID003036760
Drug6-hydroxymelatonin

CYP2A6 CYP2A7 PPIG CYP2A13

4.00e-0550874CID000001864
DrugD 703

CYP2A6 PPIG CYP2A13

4.22e-0518873CID000054088
DrugPCN 66

PPIG PLEC

4.32e-053872CID000107698
Drugdimethylbiphenyl

CYP2A6 PPIG

4.32e-053872CID000034109
DrugQuercetin

PIK3CG HCK

4.32e-053872DB04216
Drugnaphthalene epoxide

CYP2A6 CYP2A7 CYP2A13 GSTO1

4.33e-0551874CID000108063
DrugD 617

CYP2A6 PPIG CYP2A13

5.00e-0519873CID000093168
Drugaminopyrine

DMGDH CYP2A6 CYP2A7 PPIG CYP2A13 PLEC

5.02e-05171876CID000006009
Drugphenacetin

CYP2A6 PPIG CYP2A13 CNTN3

5.85e-0555874CID000004754
Drugchloroacetyl chloride

CYP2A6 CYP2A7 CYP2A13 GSTO1

5.85e-0555874CID000006577
Drug1,2-dihydroxynaphthalene

CYP2A6 CYP2A7 CYP2A13 LTA4H

6.73e-0557874CID000011318
Drugphenobarbital

DMGDH CYP2A6 CYP2A7 CYP2A13 EGFR FUS PLEC GSTO1

7.13e-05360878CID000004763
Drugbromoacetaldehyde

CYP2A6 CYP2A7 CYP2A13 GSTO1

7.21e-0558874CID000105131
Drugproadifen hydrochloride

CYP2A6 CYP2A7 PPIG CYP2A13 LTA4H

7.68e-05114875CID000004910
DrugNSC35549

CYP2A6 CYP2A7 CYP2A13

7.87e-0522873CID000411697
DrugN'-nitrosoanatabine

CYP2A6 CYP2A13

8.62e-054872ctd:C032978
DrugNMPA

CYP2A6 CYP2A13

8.62e-054872CID000132101
DrugAC1Q7AUJ

DMGDH CYP2A6 CYP2A7 CYP2A13 PLEC

8.68e-05117875CID000003303
Druggeldanamycin

ZFHX4 EGFR LMO7 MAP4K5 NKTR HEATR1 GALNT5 ESCO1

8.78e-05371878ctd:C001277
DrugNAPQI

CYP2A6 PPIG PLEC GSTO1

8.79e-0561874CID000039763
DrugBP-4,5-oxide

CYP2A6 CYP2A7 CYP2A13 GSTO1

8.79e-0561874CID000037786
Drug8-MOP

CYP2A6 CYP2A7 PPIG CYP2A13 CNTN3

9.04e-05118875CID000004114
Drugchlorzoxazone

CYP2A6 CYP2A7 PPIG CYP2A13

9.97e-0563874CID000002733
DrugAC1L44DC

CYP2A6 PPIG PLEC

1.17e-0425873CID000150456
Drugbeta-naphthoflavone

CYP2A6 CYP2A7 PPIG CYP2A13 PLEC GSTO1

1.19e-04200876CID000002361
Drugpiperonyl butoxide

CYP2A6 CYP2A7 PPIG CYP2A13

1.27e-0467874CID000005794
Drugmethoxyresorufin

CYP2A6 PPIG CYP2A13 PLEC

1.42e-0469874CID000119220
Drug3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide

CALCA EGFR

1.43e-045872ctd:C500530
Drugbenzyl selenocyanate

CYP2A6 CYP2A13

1.43e-045872ctd:C054108
Drugdi-p-tolyl

CYP2A6 PPIG

1.43e-045872CID000011941
DrugN-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide

CYP2A6 CYP2A13

1.43e-045872ctd:C062567
DrugBP-9,10-oxide

CYP2A6 CYP2A7 CYP2A13

1.48e-0427873CID000037456
DrugBrn 4136738

CYP2A6 CYP2A7 CYP2A13

1.48e-0427873CID000050331
DrugC14845

CYP2A6 CYP2A7 CYP2A13

1.48e-0427873CID011954064
Drug1,2-dibromoethane

CYP2A6 CYP2A7 CYP2A13 GSTO1

1.59e-0471874CID000007839
Drug5-nitro-1-naphthonitrile

CYP2A6 CYP2A13 ZKSCAN7

1.65e-0428873CID000031744
Drugnorverapamil

CYP2A6 PPIG CYP2A13

1.65e-0428873CID000104972
Drug9-OH-BaP-4,5-oxide

CYP2A6 CYP2A7 CYP2A13

1.65e-0428873CID000115064
Drugcarteolol

CYP2A6 CYP2A7 PPIG CYP2A13

1.68e-0472874CID000002583
DrugAroclor 1254

CYP2A6 CYP2A7 PPIG CYP2A13 PLEC GSTO1

1.68e-04213876CID000040470
Drugtrans-3'-hydroxycotinine

CYP2A6 PPIG CYP2A13

1.83e-0429873CID000000414
Drugcoumarin

CYP2A6 CYP2A7 PPIG CYP2A13 GSTO1

1.95e-04139875CID000000323
Drug7-hydroxycoumarin

CYP2A6 CYP2A7 PPIG CYP2A13

1.97e-0475874CID005281426
Drugdebrisoquine

CYP2A6 CYP2A7 PPIG CYP2A13

1.97e-0475874CID000002965
Drug19-hydroxytestosterone

CYP2A6 CYP2A7 CYP2A13

2.03e-0430873CID000150968
Drug11-H-14,15-EETA

CYP2A6 CYP2A7 CYP2A13

2.03e-0430873CID011954058
DrugCoenzyme

PPIG KDM5D

2.14e-046872CID000065625
Drugmenthofuran

CYP2A6 CYP2A13

2.14e-046872ctd:C054487
Drugacenaphthene-1-ol

CYP2A6 CYP2A13

2.14e-046872ctd:C023723
DrugAC1L196J

CYP2A6 CYP2A13

2.14e-046872CID000000415
DrugN'-nitrosoanabasine

CYP2A6 CYP2A13

2.14e-046872ctd:C010257
Drugclotrimazole

CYP2A6 PPIG LTA4H PLEC GSTO1

2.23e-04143875CID000002812
DrugC20H32O4

CYP2A6 CYP2A7 CYP2A13 LTA4H

2.29e-0478874CID000001440
DrugBP-7,8-oxide

CYP2A6 CYP2A7 CYP2A13

2.47e-0432873CID000037455
DrugNNAL

CYP2A6 CYP2A13 PLEC

2.47e-0432873CID000104856
Drugtrimipramine

CYP2A6 CYP2A7 PPIG CYP2A13

2.52e-0480874CID000005584
Drug3-methylcholanthrene

CYP2A6 CYP2A7 PPIG CYP2A13 PLEC GSTO1

2.60e-04231876CID000001674
DrugN-NK

CYP2A6 CYP2A7 PPIG CYP2A13 EGFR

2.61e-04148875CID000047289
Drug12(13)-EpOME

CYP2A6 CYP2A7 CYP2A13

2.96e-0434873CID000001416
DrugTCEO

CYP2A6 CYP2A7 CYP2A13

2.96e-0434873CID000028167
Drugacenaphthene

CYP2A6 CYP2A13

2.99e-047872ctd:C042552
Drugdiallyl phthalate

CYP2A6 PPIG

2.99e-047872CID000008560
DrugPolnoks R

CYP2A6 PPIG

2.99e-047872CID000008981
Drugchrysene-1,2-diol

CYP2A6 PPIG

2.99e-047872CID000119256
DrugAC1L1CJI

CYP2A6 CYP2A7 CYP2A13

3.23e-0435873CID000001929
Diseasecaffeine metabolite measurement

CYP2A6 CYP2A7 MAP4K5

2.24e-0519863EFO_0007872
Diseasecorpus collosum mid-posterior volume measurement

EGFR AGBL2 LNX1

5.25e-0525863EFO_0010300
Diseasefasting blood glucose measurement, glucose tolerance test, fasting blood insulin measurement

MAP4K5 VPS13C

8.35e-055862EFO_0004307, EFO_0004465, EFO_0004466
Diseasecortical thickness

EGFR WNT16 PCDHB11 PKHD1 NAV2 CHSY1 PLEC AGBL2 LNX1 CDC42EP3 KIF20B PLCE1

9.12e-0511138612EFO_0004840
DiseaseNEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE

GAPVD1 NUP133 PLCE1

9.17e-0530863C1868672
Disease2-myristoyl-GPC (14:0) measurement

MAP4K5 ESCO1

1.25e-046862EFO_0800242
Disease1-myristoyl-GPC (14:0) measurement

MAP4K5 ESCO1

1.25e-046862EFO_0800221
DiseaseSquamous cell carcinoma of esophagus

CYP2A6 EGFR GSTO1 PLCE1

1.75e-0495864C0279626
Diseaseneuroimaging measurement, brain volume measurement

BPTF EGFR ZNF184 PLEC LNX1 ESCO1

1.93e-04286866EFO_0004346, EFO_0006930
Diseasecorpus callosum volume measurement

EGFR WNT16 PLEC LNX1

2.13e-04100864EFO_0010299
Diseasebitter beverage consumption measurement

CYP2A6 MAP4K5 AGBL2

2.53e-0442863EFO_0010089
Diseaseserum urea measurement

DLGAP1 PIK3CG MAP4K5 TMEM51 PLCE1

2.70e-04195865EFO_0009795
DiseaseAutosomal Recessive Polycystic Kidney Disease

EGFR PKHD1

2.98e-049862C0085548
DiseaseCancer of Nasopharynx

CYP2A6 EGFR

2.98e-049862C0238301
DiseaseNasopharyngeal Neoplasms

CYP2A6 EGFR

2.98e-049862C0027439
Diseaseserum gamma-glutamyl transferase measurement

DMGDH BPTF CYP2A6 PLB1 GALNT3 MAP4K5 PKHD1 NAV2 DNMBP PLCE1

3.27e-049148610EFO_0004532
Diseasenicotine metabolite ratio

CYP2A6 CYP2A7

5.44e-0412862EFO_0007794
Diseaselevel of Phosphatidylcholine (14:0_18:1) in blood serum

MAP4K5 ESCO1

5.44e-0412862OBA_2045062
DiseaseAstigmatism

EGFR LMO7 CHSY1 LNX1

5.61e-04129864HP_0000483
DiseaseNeoplasm of lung

CYP2A6 EGFR

7.47e-0414862cv:C0024121
DiseaseLung cancer

CYP2A6 EGFR

7.47e-0414862cv:C0242379
DiseaseLUNG CANCER

CYP2A6 EGFR

7.47e-0414862211980
Diseasetriglycerides in small VLDL measurement

DMGDH BPTF MAP4K5

7.61e-0461863EFO_0022145
Diseaseupper aerodigestive tract neoplasm

CYP2A6 ZNF184 EIF4G2 HEATR1 LNX1

7.78e-04246865EFO_0004284
Diseasetriglycerides in small HDL measurement

DMGDH BPTF MAP4K5

7.98e-0462863EFO_0022158
Diseaseneuroimaging measurement

ANK3 EGFR WNT16 PKHD1 NAV2 PLEC LNX1 CDC42EP3 KIF20B PLCE1

1.09e-0310698610EFO_0004346
Diseasecervical artery dissection

LNX1 PLCE1

1.11e-0317862EFO_1000059
Diseasebrain measurement, neuroimaging measurement

BPTF ANK3 EGFR NAV2 PLEC LNX1 CDC42EP3

1.14e-03550867EFO_0004346, EFO_0004464
Diseaseresponse to alcohol

DLGAP1 EGFR PKHD1

1.39e-0375863EFO_0005526
Diseasecytomegalovirus virus reactivation, response to allogeneic hematopoietic stem cell transplant

DNAJC10 CDC42EP3

1.39e-0319862EFO_0007044, EFO_0020106
Diseaselevel of Phosphatidylcholine (16:1_18:2) in blood serum

MAP4K5 ESCO1

1.70e-0321862OBA_2045083
Diseaseurinary albumin to creatinine ratio

CYP2A6 CYP2A7 CWC27 MAP4K5

1.89e-03179864EFO_0007778
Diseasesmoking status measurement

BPTF CYP2A6 DLGAP1 GAPVD1 PKHD1 NAV2 CNTN3 SNRK AGBL2 ADAT1

2.00e-0311608610EFO_0006527
Diseasesphingomyelin 24:1 measurement

PCDHB11 ZNF397

2.04e-0323862EFO_0010398
Diseaseinsulin sensitivity measurement

DMGDH MAP4K5

2.04e-0323862EFO_0004471
Diseaseblood urea nitrogen measurement

DLGAP1 EGFR PIK3CG MAP4K5 PKHD1 PLCE1

2.09e-03452866EFO_0004741
Diseasealcohol use disorder measurement, alcohol dependence

MAP4K5 PKHD1

2.22e-0324862EFO_0009458, MONDO_0007079
Diseaseopen-angle glaucoma

LMO7 PKHD1 AGBL2 PLCE1

2.39e-03191864EFO_0004190
Diseasealcohol use disorder (implicated_via_orthology)

EGFR MAP4K5 KDM5D GSTO1

2.57e-03195864DOID:1574 (implicated_via_orthology)
Diseasediet measurement, bilirubin measurement

SH3D19 EIF4G2

2.61e-0326862EFO_0004570, EFO_0008111
Diseaseglucose tolerance test

MAP4K5 VPS13C

2.81e-0327862EFO_0004307
Diseasedocosapentaenoic acid measurement

SYCP2L MAP4K5

2.81e-0327862EFO_0006809
Diseasecorpus callosum mid-anterior volume measurement

PLEC LNX1

2.81e-0327862EFO_0010297
DiseaseS-warfarin measurement

EGFR CNTN3 ADPRHL1

2.89e-0397863EFO_0803323

Protein segments in the cluster

PeptideGeneStartEntry
KNNFVPTNVGSKAFG

CALCA

106

P06881
YSQPPGFSGSSQTKK

COP1

331

Q8NHY2
PKGTKNFSLLSFGEE

CWC27

196

Q6UX04
GQFKKSDAFVPFSIG

CYP2A6

421

P11509
GSPKEESRKFTNFQS

AFTPH

381

Q6ULP2
FVQITGKKPNFEVGS

CIAPIN1

156

Q6FI81
GENKAPSKFQSVGVQ

DLGAP1

666

O14490
LGKKEDVTGQFPSSF

DNMBP

41

Q6XZF7
GQEPSKSKTKGNDFF

BPTF

1326

Q12830
VTFNSKQESFGPAKL

CDC42EP3

126

Q9UKI2
SPGNASELGETFKFK

DESI2

56

Q9BSY9
TANGFPQGTTKKTIG

ADAT1

411

Q9BUB4
FKDKQNKPTGFALGS

RAE1

221

P78406
QSTVTQPGGKFAFFK

NOMO3

161

P69849
PTGKSFAINFKVGSS

LGALS4

216

P56470
QNSVKTFGETHPFTK

LTA4H

351

P09960
GTGKFSLPQEKIVFN

NUP133

431

Q8WUM0
QSTVTQPGGKFAFFK

NOMO2

161

Q5JPE7
VLTNKKTTFFGGNSI

GSTO1

156

P78417
GKEFSGNPIKVSFAT

FUS

356

P35637
NSGFGKTEFSFKPLE

MCM3AP

136

O60318
FSPSQQEKLFGEKGS

GAPVD1

226

Q14C86
SKEFGSGFPVSNSKQ

KDM5D

436

Q9BY66
TFTFAKNPGQKGLDL

DCUN1D2

161

Q6PH85
VGPGFTGNFSTQKVK

FOLH1B

21

Q9HBA9
QKFSFSKVFGPATTQ

KIF20B

111

Q96Q89
SKVFGPATTQKEFFQ

KIF20B

116

Q96Q89
QSTVTQPGGKFAFFK

NOMO1

161

Q15155
NQTPGKSLDFGFTIK

LMO7

1046

Q8WWI1
NGNKPFFIKSIVEGT

LNX1

661

Q8TBB1
NQNGTGKFVKKPASS

EDC3

96

Q96F86
NTVGKASQPSFSIKG

ODF3

151

Q96PU9
TGGSESNDFKFLKPI

PCDHB15

756

Q9Y5E8
KTAGNSEFLGKTPGQ

EIF4G2

31

P78344
EGAPASFGKSFAQKS

MVB12A

36

Q96EY5
SSTAKAFKIPGFQGQ

MOCS1

286

Q9NZB8
TGGSETNEFKFLKPV

PCDHB11

756

Q9Y5F2
GKDTNGSQFFITTKP

PPIG

116

Q13427
AKPNGIFKGSTAENA

EGFR

1181

P00533
GFVTNGKPSAIFKIS

HIKESHI

71

Q53FT3
KSKFLQVGGNTFSKT

HCK

26

P08631
NDGQPKTNKTTGFKI

GRID2IP

1031

A4D2P6
GQFKKSDAFVPFSIG

CYP2A13

421

Q16696
TTNPNTSKFAQKYGG

CSRP2

101

Q16527
GQFKKSDAFVPFSIG

CYP2A7

421

P20853
QDSNAPGASGKAFKT

GALNT3

116

Q14435
QGAPKTSFIAAKGTQ

GALNT5

166

Q7Z7M9
SSLKKNVGQFSGFPF

DEK

121

P35659
EKAGFASTLQKQPTF

AGBL2

781

Q5U5Z8
TPFNEKGSGFGAATK

ADPRHL1

121

Q8NDY3
PDKTDQKSGAQFFTL

ANK3

3491

Q12955
VTDLSPFGKFNIKGQ

DMGDH

531

Q9UI17
SQAKIDTGENKFPGS

ESCO1

536

Q5FWF5
SSNNFLKKVVESGGP

HEATR1

1526

Q9H583
AFFGTPISKASQKIS

AHCTF1

1101

Q8WYP5
FQPSLAVFKGQGTKE

DNAJC10

416

Q8IXB1
SFTPVFLGSALKNKG

GFM1

291

Q96RP9
FNTNGTLITVGFKPK

CFAP47

3091

Q6ZTR5
GAGPFSATVNVTTKK

CNTN3

886

Q9P232
NPFVDGANTGKSTSK

MAP4K5

371

Q9Y4K4
KLKPFFGGSTSINQI

OSBPL5

571

Q9H0X9
TFGKSKFAENNPGKF

RPGR

16

Q92834
AEKPIGNTFSTVSGK

SH3D19

281

Q5HYK7
KHTNGSQFFITTKPA

NKTR

116

P30414
PFTVFTINGGTKAKQ

PLCE1

2026

Q9P212
PTANANSFGFKKQSG

NAV2

1136

Q8IVL1
ETVGKKEPTGFSLNN

PPP1R32

311

Q7Z5V6
FLSAKEETPGAGQKQ

SLC43A3

251

Q8NBI5
GGFTVKTSQLKFTNS

PKHD1

2496

P08F94
EFNPSLKGFSVGTGK

PLB1

446

Q6P1J6
LTDFGFSNKFQPGKK

SNRK

156

Q9NRH2
TFKNNSPSGGETKCV

ADGRF5

941

Q8IZF2
KTIPGKVQFFSSEGS

CHSY1

111

Q86X52
GTSGKKTSPHFQKFQ

PIK3CG

996

P48736
NPFGSSNPFKSKSND

ZFHX4

2866

Q86UP3
QKFQGSVSFKDVTVG

ZNF33B

6

Q06732
PVFKGFSSSSKDQIA

SLC23A1

566

Q9UHI7
NGSAILPTFENFTKK

SYCP2L

701

Q5T4T6
GFSAAEKPTAQGSNK

TMEM51

36

Q9NW97
IKADKNGPSFQTAFG

VPS13C

996

Q709C8
KFLDFPIGNTTGKEN

WNT16

181

Q9UBV4
FKSQIPKESGTGQAE

USF3

1176

Q68DE3
TVSAPFGKFQGKTVT

PLEC

3046

Q15149
ESVSGKVNLAFKQPG

VPS26A

46

O75436
GSFSQVIFTNKSLGK

ZNF397

241

Q8NF99
LTPKQEFFKGSESSN

ZKSCAN7

281

Q9P0L1
KSSQGNGYKPSFSDV

ZNF224

146

Q9NZL3
KGPVNNEFGKSVNVS

ZNF184

176

Q99676
LKSGFNPNQGFFKTT

UBE3C

781

Q15386
GKKGSPSAQSFEELQ

TWIST2

51

Q8WVJ9